Trinity Biotech plc (NASDAQ:TRIB) saw strong trading volume on Monday . 80,234 shares traded hands during mid-day trading, an increase of 39% from the previous session’s volume of 57,552 shares.The stock last traded at $13.55 and had previously closed at $13.05.

Separately, Zacks Investment Research upgraded Trinity Biotech plc from a “sell” rating to a “hold” rating in a report on Wednesday, June 22nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $17.00.

The stock has a 50-day moving average price of $12.25 and a 200-day moving average price of $11.37. The stock has a market cap of $311.41 million and a PE ratio of 57.57.

Trinity Biotech plc (NASDAQ:TRIB) last posted its earnings results on Thursday, July 21st. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The company had revenue of $26.30 million for the quarter, compared to the consensus estimate of $24.30 million. Analysts expect that Trinity Biotech plc will post $0.14 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Trinity Biotech plc stock. Bank of Montreal Can acquired a new position in Trinity Biotech plc (NASDAQ:TRIB) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,109,258 shares of the company’s stock, valued at approximately $13,045,000. Bank of Montreal Can owned 4.78% of Trinity Biotech plc at the end of the most recent reporting period.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.